In order to screen the core targets and compounds of GSG in the treatment of NAFLD/NASH, 10 signaling pathways closely related to NAFLD/NASH pathogenesis, such as TNF signaling pathway, NF-kappa B signaling pathway, JAK-STAT signaling pathway, and apoptosis, were sorted out (Supplementary Table S4). This evidence concerns the gene SOAT1 and metabolic dysfunction-associated steatotic liver disease.